An expanded access record providing Arumakimig in Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications, sponsored by Novartis Pharmaceuticals. Temporarily not available. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Expanded access
The purpose of this registration is to list Managed Access Programs (MAPs) related to MAS825, arumakimig
CMAS825J12003M - Not yet available - Managed Access Program (MAP) to provide access to MAS825 to patients with Still's disease, including SJIA and AOSD, with MAS or ILD complications
359 studies on the registry are indexed under Arthritis, Juvenile; 95 are open to participants now.
Browse Arthritis, Juvenile studies →Novartis Pharmaceuticals is the lead sponsor of 2,711 studies on the registry; 218 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 435 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
An independent request was received from a licensed physician. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.
The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.
There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
Managed Access provision is allowed per local laws/regulations.
Patients receive arumakimig
Also known as: MAS825
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.